1312309-63-9

Basic information

• Product Name: Azido-PEG2-acid
• Synonyms: Azido-PEG2-acid;Azido-PEG3-acid;N3-PEG2-CH2CH2COOH;Azido-PEG2-propionic acid;N3-PEG2-COOH;3-[2-(2-Azidoethoxy)ethoxy]propanoic acid
• CAS NO: 1312309-63-9
• Molecular Formula: C₇H₁₃N₃O₄
• Molecular Weight: 203.19582
• Mol File: 1312309-63-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Azido-PEG2-acid(CAS DataBase Reference)
• NIST Chemistry Reference: Azido-PEG2-acid(1312309-63-9)
• EPA Substance Registry System: Azido-PEG2-acid(1312309-63-9)

Safety Data

• Hazardous Substances Data: 1312309-63-9(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation:
Azido-PEG2-acid is used as a bioconjugation agent for the formation of stable amide bonds with primary amine groups. The application reason is to facilitate the attachment of various biomolecules, such as proteins or peptides, to the PEG linker, enhancing their stability and solubility in aqueous media.
Used in Drug Delivery Systems:
Azido-PEG2-acid is used as a component in drug delivery systems for the development of targeted therapies. The application reason is to improve the solubility and bioavailability of drugs, as well as to enable site-specific drug delivery through the use of Click Chemistry to attach targeting ligands to the drug carrier.
Used in Materials Science:
Azido-PEG2-acid is used as a building block in the synthesis of functional materials for various applications. The application reason is to incorporate the PEG spacer and reactive azide group into the material's structure, allowing for the subsequent attachment of other molecules or the formation of complex architectures through Click Chemistry.
Used in Chemical Synthesis:
Azido-PEG2-acid is used as an intermediate in the synthesis of more complex molecules. The application reason is to provide a versatile platform for further chemical modifications, taking advantage of the reactivity of both the azide group and the terminal carboxylic acid.

Upstream product

• 1271728-79-0 tert-butyl 3-(2-(2-azidoethoxy)ethoxy)propanoate 
• 133803-81-3 2-methyl-2-propanyl 3-[2-(2-hydroxyethoxy)ethoxy]propanoate 
• 850090-13-0 9-(p-toluenesulfonyloxy)-3,6-diocanonanoic acid tert-butyl ester 
• 1312309-62-8 tert-butyl 3-(2-(2-((methylsulfonyl)oxy)ethoxy)ethoxy)propanoate 
• 756525-95-8 2-methyl-2-propanyl 3-[2-(2-aminoethoxy)ethoxy]propanoate 
• 1629676-61-4 3-(2-(2-(2-(dibenzylamino)ethoxy)ethoxy))tert-butyl propionate 

Downstream Products

• 1271728-78-9 C₁₀₁H₁₃₄N₂₈O₂₈ 
• 1604837-30-0 rhodamine B 3-(2-(2-azidoethoxy)ethoxy)-1-(piperazin-1-yl)propan-1-one 
• 1604837-32-2 rhodamine B 3-(2-(2-(4-((di(prop-2-yn-1-yl)amino)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)-1-(piperazin-1-yl)propan-1-one 
• 1604837-40-2 C₄₃H₅₀N₇O₅⁽¹⁺⁾ 
• 1610796-02-5 2,5-dioxopyrrolidin-1-yl-3 (2-(2-azidoethoxy)ethoxy)propanoate 

Relevant articles and documents

Synthesis of nucleobase-functionalized carbon nanotubes and their hybridization with single-stranded DNA

For the first time ssDNA (25-aptamer of mixed dA, dT, dG, and dC) was wrapped around functionalized single-walled carbon nanotubes (SWCNTs), whose external surfaces were attached to multiple triazole-(ethylene glycol)-dA ligands. This method of hybridization involved the formation of hydrogen bonds between dT of ssDNA and dA of functionalized SWCNTs. It deviates from the reported π-π stacking between the nucleobases of DNA and the external sidewalls of nanotubes. The structural properties of the functionalized SWCNTs and its ssDNA complex were characterized by spectroscopic (including CD and Raman), thermogravimetric, and microscopic (TEM) methods. The results thus obtained establish a new platform of DNA delivery by use of nanotubes as a new vehicle with great potential in biomedical applications and drug development.

Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing

The delivery of siRNAs to selectively target cells poses a great challenge in RNAi-based cancer therapy. The lack of suitable cell-targeting methods seriously restricts the advance in delivering siRNAs to extrahepatic tissues. Based on prostate-specific m

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.

CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS

The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF

The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)- butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

NOVEL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF DRUGS TO A BIOLOGICAL MOLECULE

The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)- butenedioic) group for conjugation of two or more compounds/cytotoxic agents per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

Synthesis and characterization of linker-armed fucose-based glycomimetics

Glycomimetic molecules can be used to antagonize the action of carbohydrate-binding proteins (lectins) involved in biological processes of high relevance for human and plant disease. In this paper we describe the derivatization with appropriate linkers of